Eli Lilly (LLY) Form 144 Notice — 2,000 RSU Shares to Be Sold
Rhea-AI Filing Summary
Form 144 notice for Eli Lilly & Co. (LLY) reports a proposed sale of 2,000 common shares through Morgan Stanley Smith Barney LLC on 08/28/2025 on the NYSE with an aggregate market value of $1,468,340.00. The shares were acquired as Restricted Stock Units on 02/09/2022 from the issuer and payment information is listed as N/A.
The filer reports no securities sold during the past three months. The form includes the standard representation that the selling person is not aware of undisclosed material adverse information and provides space for signature and plan-adoption dates, but those fields are not populated in the supplied content.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale notice for 2,000 RSU-derived shares valued at $1.47M; no recent sales reported.
The filing documents a proposed sale under Rule 144 of 2,000 common shares acquired as restricted stock units on 02/09/2022. The sale is scheduled through Morgan Stanley Smith Barney LLC on 08/28/2025 at the NYSE and shows an aggregate market value of $1,468,340.00. The disclosure that no shares were sold in the prior three months limits concerns about recent disposition activity. The form does not include the seller's identity, plan-adoption date, or signature in the provided text.
TL;DR: Compliance-focused filing; it contains required representations but lacks populated signature or plan-adoption details in the excerpt.
The submission appears to fulfill Rule 144 procedural disclosure by identifying the broker, class, quantity, acquisition type, and planned sale date. It reiterates the seller's representation regarding material nonpublic information and references Rule 10b5-1 planning, but the provided content does not show a signed attestation or a 10b5-1 adoption date. Those missing elements are notable for completeness but are not unusual in partial extracts.